Worledge K L, Godiska R, Barrett T A, Kink J A
Ophidian Pharmaceuticals Inc, Madison, Wisconsin, USA.
Dig Dis Sci. 2000 Dec;45(12):2298-305. doi: 10.1023/a:1005554900286.
Tumor necrosis factor (TNF) is implicated in the pathogenesis of inflammatory bowel disease. Clinical trials indicate that intravenous infusion of anti-TNF antibody is an effective therapy for Crohn's disease. An oral anti-TNF therapy may be a preferred approach, reducing systemic side effects and eliminating the inconvenience and expense of administering infusions. We tested oral avian anti-TNF antibodies in the acute and chronic phases of a rodent colitis model. Efficacy was compared to sulfasalazine and dexamethsone. Rats with chemically induced colitis were treated orally with anti-TNF antibody, placebo, or comparator. Efficacy was assessed by change in colonic weight, morphology, histology, and tissue myeloperoxidase activity. Oral anti-TNF antibody, in both the acute and chronic phases of the model, significantly decreased all inflammatory end points and proved to be more effective than sulfasalazine and dexamethasone. Oral delivery of avian anti-TNF antibodies is an effective treatment of experimental colitis and may provide advantages to current parenteral anti-TNF antibodies.
肿瘤坏死因子（TNF）与炎症性肠病的发病机制有关。临床试验表明，静脉输注抗TNF抗体是治疗克罗恩病的有效方法。口服抗TNF疗法可能是一种更优的方法，可减少全身副作用，并消除输液给药带来的不便和费用。我们在啮齿动物结肠炎模型的急性期和慢性期测试了口服禽类抗TNF抗体。将其疗效与柳氮磺胺吡啶和地塞米松进行了比较。对化学诱导结肠炎的大鼠口服抗TNF抗体、安慰剂或对照药进行治疗。通过结肠重量、形态、组织学和组织髓过氧化物酶活性的变化来评估疗效。在模型的急性期和慢性期，口服抗TNF抗体均显著降低了所有炎症指标，且证明比柳氮磺胺吡啶和地塞米松更有效。口服禽类抗TNF抗体是治疗实验性结肠炎的有效方法，可能比目前的肠胃外抗TNF抗体具有优势。
